[1] O’Donnell D E, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease 2007 update[J]. Can Respir J, 2007, 14(Suppl B): 5B-32B.
[2] JB S, KJ D, Coleman B, et al. The proportional Venn diagram of obstructive lung disease[J]. Chest, 2003, 124 (2): 474-481.
[3] De Marco R, Pesce G, Marcon A, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population[J]. PLoS One, 2013, 8 (5): 1224-1230.
[4] Marsh S E, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes[J]. Thorax, 2008, 63(9): 761-767.
[5] Gibson P G, simpson J L. The overlap syndrome of asthma and COPD: what are its features and how important is it?[J] .Thorax, 2009, 64(8):728-735.
[6] Rhee C K, Yoon H K, Yoo K H, et al. Medical utilization and cost in patients with overlap syndrome of chronic obstructive pulmonary disease and asthma[J]. COPD,2014,11(2): 163-170.
[7] Menezes A M, Montes de Oca M, Pérez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma[J]. Chest, 2014, 145(2): 297-304.
[8] Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease NHLBI/WHO Workshop Report. Updated 2011.
[9] Douwes J, Gibson P, Pekkanen J, et al. Noneosinophilic asthma: importance and possible mechanisms[J]. Thorax, 2002, 57(7): 643-648.
[10] Kitaguchi Y, Komatsu Y, Fujimoto K, et al. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma[J]. Int J Chron Obstruct Pulmon Dis, 2012, 7(1):283-289.
[11] Bumbacea D, Campbell D, Nguyen L, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma[J]. Eur Respir J, 2004, 24(1): 122-128.
[12] Skld C M. Remodeling in asthma and COPD-differences and similarities[J]. Clin Respir J, 2010, 4(Suppl 1): 20-27.
[13] Vonk J M, Jongepier H, Panhuysen C I M, et al.Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up[J]. Thorax, 2003, 58(4): 322-327.
[14] Papaiwannou A, Zarogoulidis P, Porpodis K, et al.Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature review[J].Thorac Dis,2014,6(Suppl 1):S146-151.
[15] Hardin M, Silverman E K, Barr R G, et al.The clinical features of the overlap between COPD and asthma[J]. Respir Res, 20ll, 12(27):127-128.
[16] Andersén H, Lampela P, Nevanlinna A, et al. High hospital burden in overlap syndrome of asthma and COPD[J]. Clin Respir J,2013, 7(4): 342-346.
[17] Kauppi P, Kupiainen H, Lindqvist A, et al. Overlap syndrome of asthma and COPD predicts low quality of life[J]. J Asthma, 2011, 48(3): 279-285.
[18] Miravitlles M, Soriano J B, Ancochea J, et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status[J]. Respire Med, 2013, 107(7):1053-1060.
[19] Soler-Catalufia J J, Cosio B,Izquierdo J L, et al. Consensus document on the overlap phenotype COPD asthma in COPD[J]. Arch Bronconeumol, 2012, 48(9): 331-337.
[20] Zeki A A, Schivo M, Chan A, et al. The asthma-COPD overlap syndrome: a common clinical problem in the elderly[J]. J Allergy, 2011:861926.
[21] Louie S, Zeki A A, Schivo M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations[J]. Expert Rev Clin Pharmacol, 2013, 6(2):197-219.
[22] Iwamoto H, Gao J, Koskela J. Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap[J]. Eur Respir J, 2014, 43(2): 421-429.
[23] Hardin M, Cho M, McDonald M L, et al.The clinical and genetic features of COPD-asthma overlap syndrome[J]. Eur Respir J, 2014,(44): 341-350.
[24] Miravitlles M, Soler-Catalua J J, Calle M, et al. Spanish COPD Guidelines(GesEPOC):pharmacological treatment of stable COPD[J]. Aten Primaria, 2012, 44(2): 425-437.
[25] Siva R, Green R H, Brightling C E, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial[J]. Eur Respir J, 2007, 29(5): 906-913.
[26] McDonald V, Higgins I, Wood L, et al. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense?[J]. Thorax, 2013, 68(7): 691-694.
[27] Magnussen H, Bugnas B, van Noord J, et al. Improvements with tiotropium in COPD patients with concomitant asthma[J]. Respir Med, 2008, 102(1): 50-56.
[28] Ohar J A, Donhue J F. Mono-and combination therapy of long acting brochodilators and inhaled corticosteroid in advanced COPD[J]. Semin Respir Crit Care Med, 2010, 31(3):321-333.
[29] Bjerg A, Lundback B, Lotvall J. The future of combining inhaled drugs for COPD[J]. Curr Opin Pharmacol,2012,12(3):252-255.